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abel use of bare-metal stents (BMS) had lower rates of death, myocardial infarction, target vessel
evascularization, and major adverse cardiac events at 9 months and 2 years and lower rates of
tent thrombosis at 9 months.
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406rug-eluting stents (DES) have been shown to be very
ffective in reducing target vessel revascularization
TVR) in multiple randomized trials (1,2). Drug-eluting
tents have been used with increasing frequency for
off-label” indications, but there are limited data regard-
ng the safety and efficacy of off-label use (3–5). Further-
ore, there is growing concern regarding potential in-
reased risk of late stent thrombosis, especially with
ff-label use (6).
The STENT (Strategic Transcatheter Evaluation of
ew Therapies) Group is the first and largest multicenter
rospective registry to evaluate late outcomes with DES
n the U.S. The purpose of this study is to evaluate
utcomes with off-label use of DES from the STENT
egistry and to compare outcomes of off-label use with
n-label use of DES and with off-label use of bare-metal
tents (BMS).
Methods
The STENT Group. The STENT
Group created a multicenter
registry to evaluate coronary ar-
tery stent use and outcomes in
real-world clinical settings be-
ginning in May 2003. Patients
undergoing percutaneous coro-
nary intervention (PCI) at 8 cor-
onary interventional centers
consented to participate in this
study, which included 9-month
and 2-year follow-ups. This is
the largest prospective registry
for evaluating DES in the U.S.
and is supported by unrestricted
rants from the industry. Detailed methodology of this
egistry has been previously reported (7).
eﬁnitions. Off-label use was defined as DES use in lesion
r patient subsets that have not been extensively studied in
andomized trials and for which DES does not have Food
nd Drug Administration approval (8,9). This group in-
luded patients with ST-segment elevation myocardial in-
arction (STEMI), chronic total occlusions, saphenous vein
raft lesions, bifurcation lesions, ostial lesions, left main
esions, in-stent restenotic lesions, small or large vessels
2.5 mm or 3.75 mm), long lesions (28 mm), and
ultilesion or multivessel PCI. On-label use included all
ther patients.
For outcomes at 9 months and 2 years, reinfarction was
efined as a new elevation of the myocardial band fraction of
reatine kinase 2 times the normal amount and includes
oth STEMI and non-STEMI. Target vessel revasculariza-
ion was defined as a repeat procedure anywhere in the
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
ACE  major adverse
ardiac events
CI  percutaneous
oronary intervention
TEMI  ST-segment
levation myocardial
nfarction
LR  target lesion
evascularization
VR  target vessel
evascularizationarget vessel, including repeat PCI or coronary artery bypassraft surgery. The TVR procedure was used instead of
arget lesion revascularization (TLR), because determina-
ions were assessed by the operators without a core angio-
raphic laboratory to distinguish TLR from TVR occurring
t sites other than the target lesion. Stent thrombosis was
efined using a modified Academic Research Consortium
efinition of definite or probable stent thrombosis: angio-
raphically documented stent thrombosis, a myocardial
nfarction in the distribution of the target vessel, or sudden
ardiac death.
tudy population. Our study population with 9-month
ollow-up is shown in Figure 1. Of 26,941 PCI procedures
erformed at 8 centers from May 2003 to June 2006, 24,713
atients consented to participate in the Registry (92%),
0,868 patients were unique (first procedure for a patient in
he Registry), and 19,453 had 9-month follow-up (93%). Of
hese patients, 8,897 had DES-only stents implanted for
ff-label indications, and these patients form our study
roup. Outcomes in these patients were compared with
,063 patients with on-label use of DES and with 2,131
atients with off-label use of BMS who had 9-month
ollow-up.
Our study population with 2-year follow-up is shown in
igure 2. This study population is a subgroup of the study
opulation with 9-month follow-up. Of 11,705 PCI pro-
edures performed from May 2003 through February 2005,
0,326 patients consented (88%), 8,942 patients were
nique, and 8,532 patients had 2-year follow-up (95%). Of
hese patients, 3,603 had DES-only stents implanted for
ff-label indications, and these patients form our study
Figure 1. Study Population (9-Month Follow-Up)
Our study population (9-month follow-up) consists of all patients who had
DES-only stents used for off-label indications and who had 9-month clinical
follow-up. BMS  bare-metal stent(s); DES  drug-eluting stent(s); f/u 
follow-up.
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407roup with 2-year follow-up. Outcomes in these patients
ere compared with 2,583 patients with on-label use of
ES and with 1,117 patients with off-label use of BMS
ho had 2-year follow-up.
In patients with off-label use of DES and 9-month
ollow-up, sirolimus-eluting stents were used in 49% of
atients, paclitaxel-eluting stents were used in 48% of
atients, and both types were used in 3% of patients. In
atients with on-label use of DES and 9-month follow-up,
irolimus-eluting stents were used in 49% of patients and
aclitaxel-eluting stents were used in 51% of patients.
ata collection. All data were collected prospectively by
tudy coordinators at participating hospitals. Procedural
ata, including adjunctive pharmacology, device utilization,
eference vessel diameter, lesion length, and lesion charac-
Figure 2. Study Population (2-Year Follow-Up)
Our study population (2-year follow-up) consists of all patients who had
DES-only stents used for off-label indications and who had 2 year clinical
follow-up. Abbreviations as in Figure 1.
Table 1. Baseline Characteristics
On-Label DES
(n  6,063)
Off-Label DE
(n  8,897
Age, yrs (mean  SD) 62.9 11.5 63.1 11.8
Female 2,194 (36.2) 2,905 (32.7)
Diabetes 1,937 (32.0) 2,966 (33.3)
Hypertension 4,542 (74.9) 6,622 (74.4)
Hyperlipidemia 3,763 (62.1) 5,350 (60.1)
Ever smoker 3,667 (60.5) 5,386 (60.5)
Prior infarction 1,277 (21.1) 2,105 (23.7)
Prior bypass surgery 662 (10.9) 1,724 (19.4)
Prior PCI 1,491 (24.6) 2,453 (27.6)
STEMI 0 (0.0) 1,450 (16.3)
Values are n (%) unless otherwise noted. p Value 1: off-label DES versus on-label DES use. p Value 2:BMS bare-metal stent(s); DES drug-eluting stent(s); PCI percutaneous coronary intervention; STEMeristics (including off-label versus on-label indications)
ere assessed by the operating interventional cardiologist
nd were recorded at the conclusion of each procedure.
omprehensive chart reviews were performed for the index
ospitalization for each patient shortly after discharge.
ost-discharge clinical follow-up was conducted by tele-
hone interview at 9 and 24 months after the procedure.
omplete hospital records were reviewed for every patient
eporting a cardiac event following the index hospitaliza-
ion. All data were entered into a centralized database for
uality control and statistical analysis (R. Stuart Dickson
nstitute for Health Studies, Charlotte, North Carolina).
hysicians adjudicated all major events including death,
VR, and stent thrombosis, and audits were performed on
0% of the first 4,000 procedures and 5% thereafter.
tatistical methods. Baseline and outcome variables were
ompared using t tests for continuous variables and the
hi-square test or Fisher exact test for categorical variables.
p value  0.05 was considered statistically significant. All
nalyses were performed using SAS version 9.1 (SAS
nstitute Inc., Cary, North Carolina).
Kaplan-Meier event curves were constructed for TVR,
eath or myocardial infarction, and stent thrombosis for
ach subgroup, and comparisons between subgroups were
ade with log-rank tests.
When adjusting for differences in baseline risk profile
etween off-label DES use versus on-label DES use, Cox
roportional hazards regression models were used. Variables
ncluded in the model were site, age, gender, diabetes,
ypertension, hyperlipidemia, smoking status, prior infarc-
ion, prior bypass surgery, and prior PCI. Clinical acuity
STEMI, non–ST-segment elevation acute coronary syn-
rome, or stable angina) and angiographic variables were
ot included, because these were used to define off-label use.
hen adjusting for differences in baseline risk between
ff-label DES use and off-label BMS use, propensity anal-
sis was used. Propensity scores were calculated with a
Off-Label BMS
(n  2,131) p Value 1 p Value 2
65.4 12.3 0.24 0.0001
635 (29.8) 0.0001 0.01
631 (29.6) 0.08 0.0001
1,529 (71.8) 0.52 0.01
1,036 (48.6) 0.02 0.0001
1,318 (61.9) 0.95 0.27
527 (24.7) 0.0002 0.3
559 (26.2) 0.0001 0.0001
572 (26.8) 0.0001 0.52
631 (29.6) — 0.0001
l DES versus off-label BMS use.S
)
off-labeI ST-segment elevation myocardial infarction.
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408ogistical regression model that included all demographic,
linical, and angiographic variables, including variables used
o define off-label use. The ability of the propensity score to
ffectively balance off-label DES use and off-label BMS use
Table 2. Angiographic and Procedural Characteristics
On-Label DES
(n  6,063)
Target lesion (n) 6,063
Left main 0 (0.0)
Left anterior descending 2,421 (39.9)
Circumﬂex 1630 (26.9)
Right coronary artery 2,012 (33.2)
Saphenous vein graft 0 (0.0)
Ejection fraction % (mean  SD) 52.5 11.3
Reference vessel diameter, mm (mean  SD) 3.0 0.4
Lesion length, mm (mean  SD) 14.4 5.8
Stent length, mm (mean  SD) 20.1 7.6
Number of stents/procedure 1.07 0.29
Adjunctive pharmacology
Glycoprotein IIb/IIIa platelet inhibitor 3,224 (53.2)
Bivalirudin 2,017 (33.3)
Enoxaparin 444 (7.3)
Multivessel PCI 0 (0.0)
Multilesion PCI 0 (0.0)
Angiographic success 6,020 (99.3)
Values are n (%) unless otherwise noted. Target lesion is expressed as the number of target lesions
expressed at the number of lesions treated successfully (final stenosis 50%and TIMI flowgrade 2
p Value 2: off-label DES versus off-label BMS use.
Abbreviations as in Table 1.
Table 3. Outcomes
On-Label DES Off-Label DES Off-L
Outcomes at 9 months (n  6,063) (n  8,897) (n
Death 118 (2.0) 304 (3.4) 14
Myocardial infarction 124 (2.1) 270 (3.0) 10
Death/myocardial infarction 228 (3.8) 538 (6.1) 23
TVR 189(3.1) 498 (5.6) 16
MACE 391(6.5) 929 (10.4) 35
Stent thrombosis 37 (0.6) 88 (1.0) 3
Outcomes at 2 years (n  2,583) (n  3,603) (n
Death 130 (5.0) 243 (6.7) 14
Myocardial infarction 87 (3.4) 177 (4.9) 8
Death/myocardial infarction 202 (7.8) 392 (10.9) 20
TVR 163 (6.3) 415 (11.5) 14
MACE 333 (12.9) 717 (19.9) 30
Stent thrombosis 23 (0.9) 54 (1.5) 2
Values are n (%) unless otherwise noted. p Value 1 andHazard Ratio 1 compare off-label DESwith on-
2 and Hazard Ratio 2 compare off-label DES with off-label BMS use. Hazard ratios are assessed withMACEmajor adverse cardiac events include death, myocardial infarction, or target revascularization; Tt baseline is shown in the Online Appendix Table. The
redictive ability of the propensity score was assessed by the
-statistic. Propensity scores were entered into the Cox
roportional hazards regression model as a covariate along
bel DES
8,897)
Off-Label BMS
(n  2,131) p Value 1 p Value 2
4,867 3,002
23 (1.5) 28 (0.9) 0.0001 0.0001
37 (35.9) 676 (22.5)
56 (21.9) 575 (19.2)
47 (33.9) 1,267 (42.2)
95 (6.7) 453 (15.1)
 12.2 47.7 13.2 0.0001 0.0001
 0.5 3.3 0.8 0.3 0.0001
 11.2 15.6 9.6 0.0001 0.0001
 13.2 21.0 11.3 0.0001 0.0001
 0.85 1.47 0.74 0.0001 0.0001
35 (55.5) 1,256 (58.9) 0.006 0.004
97 (31.4) 345 (16.2) 0.02 0.0001
00 (7.9) 226 (10.6) 0.22 0.0001
01 (20.2) 207 (9.7) — 0.0001
28 (53.1) 689 (32.3) — 0.0001
64 (97.3) 2,924 (97.4) 0.0001 0.8
as a percentage of the total number of lesions treated in each subgroup. Angiographic success is
ercentage of total lesions treated in each subgroup. p Value 1: off-label DES versus on-label DES use.
Unadjusted Adjusted
MS p Value 1 p Value 2
Hazard Ratio 1
(95% CI)
Hazard Ratio 2
(95% CI)
1)
0.0001 0.0001 1.75 (1.41–2.16) 0.55 (0.43–0.70)
0.0001 0.0001 1.45 (1.17–1.80) 0.50 (0.38–0.65)
) 0.0001 0.0001 1.60 (1.37–1.67) 0.53 (0.44–0.64)
0.0001 0.0006 1.79 (1.51–2.12) 0.48 (0.39–0.60)
) 0.0001 0.0001 1.62 (1.43–1.82) 0.51 (0.44–0.59)
0.01 0.04 1.62 (1.10–2.39) 0.51 (0.31–0.82)
7)
) 0.006 0.0001 1.29 (1.04–1.60) 0.54 (0.42–0.70)
0.003 0.004 1.37 (1.05–1.77) 0.62 (0.45–0.86)
) 0.0001 0.0001 1.34 (1.13–1.60) 0.57 (0.46–0.70)
) 0.0001 0.37 1.87 (1.55–2.24) 0.61 (0.48–0.77)
) 0.0001 0.0001 1.55 (1.36–1.77) 0.57 (0.49–0.68)
0.04 0.28 1.59 (0.97–2.61) 0.65 (0.36–1.18)
ES use. Hazard ratios are assessed directlywith Cox proportional hazards regressionmodels. p Value
sity scores entered into Cox proportional hazards regression models.Off-La
(n 
1
2
5,3
32
5,0
9
50.3
3.0
17.0
23.9
1.74
4,9
2,7
7
1,8
4,7
14,4
treated
) as a pabel B
 2,13
6 (6.9)
6 (5.0)
3 (10.9
2 (7.6)
1 (16.5
3 (1.6)
 1,11
8 (13.3
1 (7.3)
8 (18.6
0 (12.5
8 (27.6
2 (2.0)
label D
propenVR target lesion revascularization; other abbreviations as in Table 1.
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409ith variables that were not balanced in the propensity
odels.
esults
aseline clinical variables and angiographic and procedural
haracteristics. Patients with off-label compared with on-
abel use of DES had a higher incidence of prior infarction,
rior bypass surgery, and prior PCI, but were less often
emale (Table 1). Patients with off-label use of DES also
ad lower ejection fraction, longer lesions, longer stent
ength, more stents/procedure, more glycoprotein IIb/IIIa
latelet inhibitor use, and lower angiographic success rates
Table 2).
Patients with off-label use of DES compared with off-
Figure 3. Comparison of Event Rates Between Off-Label and On-Label Use
Kaplan-Meier estimates comparing event rates at 9 months and 2 years betwe
(B) death or myocardial infarction (Death/MI), and (C) stent thrombosis (ST). Aabel use of BMS were younger, more often female, and had wigher rates of diabetes, hypertension, and hyperlipidemia,
ut a lower incidence of prior bypass surgery and STEMI
Table 1). Patients with off-label DES use have a higher
requency of left anterior descending artery PCI, lower
requency of saphenous vein graft PCI, higher ejection
raction, longer lesion length, longer stent length, more
tents/procedure, less glycoprotein IIb/IIIa platelet inhibitor
se, and more multivessel and multilesion PCI (Ta-
le 2).
utcomes of off-label DES use versus on-label DES use. Off-
abel use of DES compared with on-label use of DES had
igher rates of death, myocardial infarction, TVR, major
dverse cardiac events (MACE: such as death, myocardial
nfarction, or TVR) and stent thrombosis at the 9-month
nd 2-year follow-ups (Table 3, Fig. 3). After adjustments
-label and on-label use of DES: (A) target vessel revascularization (TVR),
ations as in Figure 1.of DES
en offith Cox proportional hazards regression models, all event
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410ates were significantly higher with off-label use at 9 months
nd 2 years, with the exception of stent thrombosis at 2 years.
When patients with STEMI were excluded from the off-label
ES use group, all adjusted event rates were still significantly
igher with off-label DES use at 9 months and 2 years.
utcomes of off-label DES use versus off-label BMS use. Off-
abel use of DES compared with off-label use of BMS had
ignificantly lower rates of death, myocardial infarction,
VR, and MACE at the 9-month and 2-year follow-ups
Table 3, Fig. 3). After adjustments with propensity analy-
es, each of these event rates remained significantly lower
ith DES versus BMS (Table 3). The predictive ability of
he propensity score model was very good with a C-statistic
f 0.80.
Stent thrombosis was significantly less frequent with
Figure 4. Comparison of Event Rates Between Off-Label Use of DES and BM
Kaplan-Meier estimates comparing event rates at 9 months and 2 years betwe
Abbreviations as in Figures 1 and 3.ff-label DES use versus off-label BMS use at 9 months, 5oth before and after adjustments, but was not significantly
ifferent at 2 years (Table 3, Fig. 4). There was a mild trend
or higher rates of stent thrombosis from 1 to 2 years with
ES versus BMS (20 of 3,569 or 0.6% vs. 2 of 1,095 or
.2%, p  0.13).
Unadjusted outcomes with DES in the 12 subgroups of
ff-label use are shown in Table 4. Comparison of outcomes
etween DES and BMS in the 12 subgroups showed
onsistently lower event rates and lower propensity adjusted
azard ratios for TVR and death or myocardial infarction
ith DES use (Fig. 5).
iscussion
ur study found that off-label use of DES comprises about
-label use of DES and off-label use of BMS: (A) TVR, (B) death/MI, and (C) ST.S
en off9% of all DES use. Patients with off-label DES use had a
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411igher risk clinical profile and higher risk lesion profile
ompared with patients with on-label DES use. Off-label
se of DES was associated with significantly higher rates of
eath, myocardial infarction, TVR, and MACE at 9
onths and 2 years and significantly higher rates of stent
hrombosis at 9 months. After adjusting for differences in
linical variables, event rates were still significantly higher
ith off-label use, reflecting the higher risk clinical profile
STEMI patients) and higher risk lesion profile that
ould not be adjusted with the multivariable analyses.
lthough event rates were higher with off-label use of
ES compared with on-label use, outcomes were still
ery good with low rates of TVR and stent thrombosis at
months and 2 years.
We also compared outcomes in patients treated with
ff-label use of DES with outcomes in patients treated with
ff-label use of BMS. Off-label DES use compared with
ff-label BMS use was associated with lower adjusted rates
or death, myocardial infarction, TVR, and MACE. The
requency of stent thrombosis was lower with off-label DES
se versus off-label BMS use at both the 9-month and
-year follow-ups, but the differences were statistically
ignificant only at 9 months. Although the 12 subcategories
f off-label use are very diverse, the reduction in the
requency of TVR and death or myocardial infarction was
ery similar across all subgroups.
Our findings are similar to results from previous registries
omparing off-label with on-label use of DES (3,4). The
.E.S. Cover Registry evaluated 2,588 patients treated with
ES for off-label or untested indications (3). After adjust-
ng for differences in baseline variables, TVR was signifi-
antly higher and there were trends for higher rates of death,
yocardial infarction, and stent thrombosis with off-label
ersus on-label use. Despite this, absolute event rates with
ff-label use were quite low (TVR 7.6% and stent throm-
osis 0.7% at 1 year), which is similar to our study. The
VENT (Evaluation of Drug-Eluting Stents and Ischemic
vents) Registry compared outcomes with off-label versus
n-label DES use and found higher rates of TLR (6.3% vs.
.4%), MACE (17.5% vs. 8.9%), and stent thrombosis
1.6% vs. 0.9%) at 1 year with off-label use (4). These
ifferences were significant after adjustments for differences
n baseline variables.
Several registries have evaluated the unrestricted use of
ES, and these registries have included large numbers of
atients with off-label use (10–12). Iakovou et al. (10)
valuated 2,229 patients treated with DES in a real-world
etting in Germany and Italy and found a frequency of stent
hrombosis of 1.3%, which is somewhat higher than that
een with on-label use in randomized clinical trials. The
-Cypher Registry evaluated 15,157 patients treated with
nrestricted utilization of sirolimus-eluting stents and found
elatively low frequencies of TLR (3.1%) and stent throm-bosis (0.9%) at 1 year (11). The ARRIVE I and II RegistriesT O O V
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412Taxus Peri-Approval Registry, A U.S. Multi-Center Safety
urveillance Program) evaluated the expanded use of
aclitaxel-eluting stents in 7,307 patients, 64% of whom
ad off-label use, and found a relatively low frequency of
VR (5.1%) and MACE (cardiac death, myocardial infarc-
ion, or TVR) (6.5%) at 1 year (12). Stent thrombosis
ccurred in 1.8% of patients at 1 year and 0.7% of patients
rom 1 to 2 years, which is somewhat higher than the
requency seen with on-label use in randomized trials.
Recently, Maroquin et al. (5) reported the results from
Figure 5. Comparison of Event Rates Between DES and BMS in Subgroups
Adjusted 9-month outcomes in subgroups of off-label use comparing rates of
chronic total occlusion; ISR  in-stent restenosis; LL  long lesion; LM  left m
tion; MV  multivessel percutaneous coronary intervention; STEMI  ST-segm
graft; other abbreviations as in Figures 1 and 3.he National Heart, Lung, and Blood Institute Dynamic tegistry comparing outcomes in patients treated with DES
ersus BMS for off-label indications. Drug-eluting stents
ere associated with lower rates of TVR and similar rates of
eath or myocardial infarction. Several registries have com-
ared outcomes with DES versus BMS in unrestricted
opulations that contain large percentages of patients with
ff-label use (13–15). The RESEARCH (Rapomycin-
luting Stent Evaluated At Rotterdam Cardiology Hospi-
al) Registry and the National Heart, Lung, and Blood
nstitute Dynamic Registry compared outcomes in patients
f-Label Use
nd death/MI between DES and BMS. BIFUR  bifurcation lesion; CTO 
rtery; LV  large vessel; ML  multilesion percutaneous coronary interven-
vation myocardial infarction; SV  small vessel; SVG  saphenous veinof Of
TVR a
ain a
ent elereated with DES with outcomes in patients who had BMS
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413mplanted before the availability of DES (13,14). Both
egistries found less TVR with DES but no differences in
eath or myocardial infarction. The large SCAAR (Swedish
oronary Angiography and Angioplasty Registry) registry
nitially reported a higher incidence of death and death or
yocardial infarction at 3 years with DES compared with
MS (15). However, further analysis with additional pa-
ients (35,000) showed no differences in death or death or
yocardial infarction at late follow-up (1 to 4 years)
etween DES and BMS (16). Tu et al. (17) reported data
rom the Ontario Registry showing lower rates of TVR and
eath at 2 and 3 years with DES compared with BMS in
roups that were matched with propensity scoring. Some of
he differences in event rates between the various registries
ay be explained by differences in definitions of myocardial
nfarction as well as differences in patient populations.
There are limited data from randomized trials comparing
ES with BMS in subgroups of off-label use. Although
here have been several randomized trials evaluating DES
ersus BMS in STEMI patients, the number of patients has
een relatively small, the follow-up has been relatively short,
nd TVR has been influenced by mandated follow-up
ngiography in most trials (18–21). Randomized trials have
een performed in only a few of the remaining subgroups,
nd the number of patients has been small and the
ollow-up has been generally short (22–27).
tudy limitations. Although our study provides an opportu-
ity to look at real-world outcomes with off-label use of
ES, it has the limitations of an observational database.
here may be hidden biases to choose BMS for sicker
atients who may have multiple comorbidities, bleeding
isk, or who may be noncompliant with dual antiplatelet
herapy as well as other therapies. It is unlikely that these
iases can be accounted for by statistical adjustments. It is
lso difficult to adjust for differences in risk profile in
omparing outcomes between off-label and on-label DES
se, because criteria used to define off-label use by definition
annot be included in the statistical model.
Our registry also does not have data regarding compliance
ith dual antiplatelet therapy. This is an important limita-
ion, because compliance with clopidogrel and aspirin is a
ajor determinant of stent thrombosis and adverse events
28,29).
onclusions
his is the largest U.S. registry to evaluate outcomes with
ff-label use of DES. Our study shows that off-label use
ompared with on-label use of DES is associated with
igher event rates at the 9-month and 2-year follow-ups,
hich is consistent with the higher risk clinical and lesion
rofile of patients with off-label use. In contrast, off-label
se of DES is associated with lower rates of death, myo-
ardial infarction, TVR, and MACE at 9 months and 2
1ears compared with off-label use of BMS. Stent thrombosis
as significantly lower at 9 months but not at 2 years.
Therefore, although event rates with off-label use of
ES are higher than with on-label use, outcomes are still
emarkably good and are better than with off-label use of
MS. Adequately powered randomized trials with long-
erm follow-up will be needed to determine the safety
nd efficacy of DES versus BMS in the numerous diverse
ubgroups of off-label use. Until the results of large
andomized trials are available, our data support the use of
ES in selected patients in most subgroups of off-label use.
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APPENDIX
TENT Registry Study Centers: Carolinas Medical Center, Charlotte, North
arolina; High Point Regional Hospital, High Point, North Carolina; Indiana
eart Institute, Indianapolis, Indiana; Moore Regional Medical Center, Pine-
urst, North Carolina; Moses H. Cone Heart and Vascular Center/LeBauer
ardiovascular Research, Greensboro, North Carolina; McLeod Regional
edical Center, Florence, South Carolina; Sisters of Charity Providence
ospitals, Columbia, South Carolina; Wellmont Holston Valley Medical
enter, Kingsport, Tennessee.
or a table on propensity adjustments, please see the online version of this
rticle.
